AP NEWS

Global Genetic Disorders Partnering 2012-2018: Latest Deal Trends, Players and Financials - ResearchAndMarkets.com

October 3, 2018

DUBLIN--(BUSINESS WIRE)--Oct 3, 2018--The “Global Genetic Disorders Partnering 2012-2018: Deal trends, players and financials” report has been added to ResearchAndMarkets.com’s offering.

The Global Genetic Disorders Partnering 2012-2018 report provides comprehensive access to available deals and contract documents for over 400 genetic disorders deals.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Genetic Disorders disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genetic Disorders deals.

The report presents financial deal terms values for Genetic Disorders deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

In Global Genetic Disorders Partnering 2012 to 2018, available deals and contracts are listed by:

Headline value Upfront payment value Royalty rate value Stage of development at signing Deal component type Technology type Specific therapy indication

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Genetic Disorders dealmaking

2.1. Introduction

2.2. Genetic Disorders partnering over the years

2.3. Genetic Disorders partnering by deal type

2.4. Genetic Disorders partnering by industry sector

2.5. Genetic Disorders partnering by stage of development

2.6. Genetic Disorders partnering by technology type

2.7. Genetic Disorders partnering by therapeutic indication

Chapter 3 - Financial deal terms for Genetic Disorders partnering

3.1. Introduction

3.2. Disclosed financials terms for Genetic Disorders partnering

3.3. Genetic Disorders partnering headline values

3.4. Genetic Disorders deal upfront payments

3.5. Genetic Disorders deal milestone payments

3.6. Genetic Disorders royalty rates

Chapter 4 - Leading Genetic Disorders deals and dealmakers

4.1. Introduction

4.2. Most active in Genetic Disorders partnering

4.3. List of most active dealmakers in Genetic Disorders

4.4. Top Genetic Disorders deals by value

Chapter 5 - Genetic Disorders contract document directory

5.1. Introduction

5.2. Genetic Disorders partnering deals where contract document available

Chapter 6 - Genetic Disorders dealmaking by therapeutic target

6.1. Introduction

6.2. Deals by Genetic Disorders therapeutic target

Appendices

Appendix 1 - Directory of Genetic Disorders deals by company A-Z 2012 to 2018

Appendix 2 - Directory of Genetic Disorders deals by deal type 2012 to 2018

Appendix 3 - Directory of Genetic Disorders deals by stage of development 2012 to 2018

Appendix 4 - Directory of Genetic Disorders deals by technology type 2012 to 2018

For more information about this report visit https://www.researchandmarkets.com/research/582p96/global_genetic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181003005429/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Pharmaceuticals

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 10/03/2018 07:26 AM/DISC: 10/03/2018 07:26 AM

http://www.businesswire.com/news/home/20181003005429/en

AP RADIO
Update hourly